Context Therapeutics Inc. (NASDAQ:CNTX) Stock Position Lifted by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC increased its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 392.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,619,140 shares of the company’s stock after purchasing an additional 1,290,323 shares during the period. Affinity Asset Advisors LLC owned 2.16% of Context Therapeutics worth $3,246,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Opaleye Management Inc. acquired a new position in shares of Context Therapeutics during the 4th quarter valued at $1,102,000. Renaissance Technologies LLC raised its position in Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares in the last quarter. Ally Bridge Group NY LLC boosted its position in shares of Context Therapeutics by 159.8% during the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after purchasing an additional 1,160,281 shares in the last quarter. Finally, Great Point Partners LLC acquired a new position in shares of Context Therapeutics in the 2nd quarter worth approximately $14,876,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Stock Down 5.8 %

CNTX stock opened at $1.96 on Wednesday. Context Therapeutics Inc. has a one year low of $0.77 and a one year high of $2.75. The firm has a 50-day moving average of $2.31 and a two-hundred day moving average of $1.90.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. As a group, equities research analysts predict that Context Therapeutics Inc. will post -0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a report on Monday.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.